The importance of combined radiation and endocrine therapy in locally advanced prostate cancer

Por Gray, Phillip J, Shipley, William U
Publicado em 2012

The opportunity cost of androgen suppression in locally advanced prostate cancer

Por Gray, Phillip J, Efstathiou, Jason A, Shipley, William U
Publicado em 2013

ADT for prostate cancer: true love or heartbreak?

Por Efstathiou, Jason A., Shipley, William U., Zietman, Anthony L., Smith, Matthew R.
Publicado em 2010

Radiation Dose–Volume Effects Of The Urinary Bladder

Por Viswanathan, Akila N., Yorke, Ellen D., Marks, Lawrence B., Eifel, Patricia J., Shipley, William U.
Publicado em 2010

Potential Surrogate Endpoints for Prostate Cancer Survival: Analysis of a Phase III Randomized Trial

Por Ray, Michael E., Bae, Kyounghwa, Hussain, Maha H. A., Hanks, Gerald E., Shipley, William U., Sandler, Howard M.
Publicado em 2009

Late Pelvic Toxicity After Bladder-Sparing Therapy in Patients With Invasive Bladder Cancer: RTOG 89-03, 95-06, 97-06, 99-06

Por Efstathiou, Jason A., Bae, Kyounghwa, Shipley, William U., Kaufman, Donald S., Hagan, Michael P., Heney, Niall M., Sandler, Howard M.
Publicado em 2009

Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31

Por Efstathiou, Jason A., Bae, Kyounghwa, Shipley, William U., Hanks, Gerald E., Pilepich, Miljenko V., Sandler, Howard M., Smith, Matthew R.
Publicado em 2009

Diabetes and Mortality in Men With Locally Advanced Prostate Cancer: RTOG 92-02

Por Smith, Matthew R., Bae, Kyounghwa, Efstathiou, Jason A., Hanks, Gerald E., Pilepich, Miljenko V., Sandler, Howard M., Shipley, William U.
Publicado em 2008

Obesity and Mortality in Men With Locally Advanced Prostate Cancer: Analysis of RTOG 85-31

Por Efstathiou, Jason A., Bae, Kyounghwa, Shipley, William U., Hanks, Gerald E., Pilepich, Miljenko V., Sandler, Howard M., Smith, Matthew R.
Publicado em 2007

Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with...

Por Mitin, Timur, Hunt, Daniel, Shipley, William U, Kaufman, Donald S, Uzzo, Robert, Wu, Chin-Lee, Buyyounouski, Mark K, Sandler, Howard, Zietman, Anthony L
Publicado em 2013

Impact of Biochemical Failure Classification on Clinical Outcome: A Secondary Analysis of Radiation Therapy Oncology Group 9202 and 9413

Por Hamstra, Daniel A., Bae, Kyounghwa, Hanks, Gerald, Hu, Chen, Shipley, William U., Pan, Charlie C., Roach, Mack, Lawton, Colleen A., Sandler, Howard M.
Publicado no Cancer (2014)

Long-Term Outcomes in Patients With Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Gro...

Por Mak, Raymond H., Hunt, Daniel, Shipley, William U., Efstathiou, Jason A., Tester, William J., Hagan, Michael P., Kaufman, Donald S., Heney, Niall M., Zietman, Anthony L.
Publicado no J Clin Oncol (2014)

The Importance of Protein Kinase A in Prostate Cancer: Relationship to Patient Outcome in Radiation Therapy Oncology Group Trial 92-02

Por Pollack, Alan, Bae, Kyounghwa, Khor, Li-Yan, Al-Saleem, Tahseen, Hammond, M. Elizabeth, Venkatesan, Varagur, Byhardt, Roger W., Asbell, Sucha O., Shipley, William U., Sandler, Howard M.
Publicado em 2009

SURVIVIN IS A POTENTIAL MEDIATOR OF PROSTATE CANCER METASTASIS

Por Zhang, Min, Coen, John J., Suzuki, Yoshiyuki, Siedow, Michael R., Niemierko, Andrzej, Khor, Li-Yan, Pollack, Alan, Zhang, Yifen, Zietman, Anthony L., Shipley, William U., Chakravarti, Arnab
Publicado no Int J Radiat Oncol Biol Phys (2010)

THE PROGNOSTIC VALUE OF SURVIVIN IN LOCALLY ADVANCED PROSTATE CANCER: A STUDY BASED ON RTOG 8610

Por Zhang, Min, Ho, Alex, Hammond, Elizabeth H., Suzuki, Yoshiyuki, Bermudez, R. Scott, Lee, R. Jeffrey, Pilepich, Michael, Shipley, William U., Sandler, Howard, Khor, Li-Yan, Pollack, Alan, Chakravarti, Arnab
Publicado em 2008

Bladder Preservation Therapy for Muscle-Invading Bladder Cancers on Radiation Therapy Oncology Group Trials 8802, 8903, 9506, and 9706: Vascular Endothelial Growth Factor B Overexp...

Por Lautenschlaeger, Tim, George, Asha, Klimowicz, Alexander C., Efstathiou, Jason A., Wu, Chin-Lee, Sandler, Howard, Shipley, William U., Tester, William J., Hagan, Michael P., Magliocco, Anthony M., Chakravarti, Arnab
Publicado em 2013

Radiotherapy treatment of early stage prostate cancer with IMRT and protons: a treatment planning comparison

Por Trofimov, Alexei, Nguyen, Paul L., Coen, John J., Doppke, Karen P., Schneider, Robert J., Adams, Judith A., Bortfeld, Thomas R., Zietman, Anthony L., DeLaney, Thomas F., Shipley, William U.
Publicado em 2007

Bcl-2 and Bax Expression Predict Prostate Cancer Outcome in Men Treated with Androgen Deprivation and Radiotherapy on Radiation Therapy Oncology Group Protocol 92-02

Por Khor, Li Yan, Moughan, Jennifer, Al-Saleem, Tahseen, Hammond, Elizabeth H., Venkatesan, Varagur, Rosenthal, Seth A., Ritter, Mark A., Sandler, Howard M., Hanks, Gerald E., Shipley, William U., Pollack, Alan
Publicado em 2007

Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Blad...

Por Mitin, Timur, George, Asha, Zietman, Anthony L., Heney, Niall M., Kaufman, Donald S., Uzzo, Robert G., Dreicer, Robert, Wallace, H. James, Souhami, Luis, Dobelbower, M. Chris, Sandler, Howard M., Shipley, William U.
Publicado no Int J Radiat Oncol Biol Phys (2015)

Randomized Trial Comparing Conventional-Dose With High-Dose Conformal Radiation Therapy in Early-Stage Adenocarcinoma of the Prostate: Long-Term Results From Proton Radiation Oncol...

Por Zietman, Anthony L., Bae, Kyounghwa, Slater, Jerry D., Shipley, William U., Efstathiou, Jason A., Coen, John J., Bush, David A., Lunt, Margie, Spiegel, Daphna Y., Skowronski, Rafi, Jabola, B. Rodney, Rossi, Carl J.
Publicado em 2010